rytelo

$4.59 +0.70 (+17.99%) (As of 06/7/2024 ET) 52-Week Range $1.64 ▼ $5.15 Price Target $6.10 The recent FDA approval of RYTELO™ (imetelstat) has propelled Geron Corporation NASDAQ: GERN into the spotlight, sparking a surge in Geron’s stock price and attracting heightened attention from investors seeking opportunities within the healthcare sector and biotech sector. This momentous achievement…